RBC Capital analyst Leonid Timashev raised the firm’s price target on Bicycle Therapeutics (BCYC) to $27 from $25 and keeps an Outperform rating on the shares after its Q2 results. The firm’s conversations with the management indicated that the Duravelo-2 dose selection update remains on track, and the program has a good likelihood of advancing forward, the analyst tells investors in a research note. RBC adds that it continues to believe zelenectide can deliver competitive efficacy to Padcev with a better safety profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics price target lowered to $44 from $48 at Oppenheimer
- Bicycle Therapeutics: Strategic Restructuring and Promising Pipeline Drive Buy Rating
- Bicycle Therapeutics files $500M mixed securities shelf
- Bicycle Therapeutics: Strategic Cost Reduction and Program Advancements Justify Buy Rating
- Bicycle Therapeutics Appoints Charles Swanton to Board